Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Tanvex Biopharma (6541) Income Statement

Tanvex Biopharma Income Statement

Last quarter (Q2 2026), Tanvex Biopharma's total revenue was NT$220.44M, an increase of 370.84% from the same quarter last year. In Q2, Tanvex Biopharma's net income was NT$-382.53M. See Tanvex Biopharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement
Income StatementDec 25Dec 24Dec 23Dec 22Dec 21
NT$ 400.97MNT$ 34.68MNT$ 61.41MNT$ 22.40MNT$ 5.41M
NT$ -440.71MNT$ 8.29MNT$ 59.70MNT$ -19.35MNT$ 3.55M
NT$ 947.48MNT$ 1.37BNT$ 2.16BNT$ 1.59BNT$ 1.60B
Depreciation and AmortizationNT$ 366.73MNT$ 289.04MNT$ 324.83MNT$ 281.56MNT$ 243.58M
NT$ -1.02BNT$ -1.04BNT$ -1.75BNT$ -1.30BNT$ -1.25B
NT$ -1.39BNT$ -1.36BNT$ -2.10BNT$ -1.59BNT$ -1.50B
NT$ -115.02MNT$ -24.46MNT$ -35.92MNT$ -35.59MNT$ 55.99M
NT$ -1.50BNT$ -1.38BNT$ -2.14BNT$ -1.64BNT$ -1.54B
NT$ -1.50BNT$ -1.38BNT$ -2.14BNT$ -1.64BNT$ -1.54B
Per Share Metrics
Basic EPSNT$ -6.13NT$ -8.90NT$ -16.42NT$ -13.55NT$ -13.80
Diluted EPSNT$ -6.13NT$ -8.90NT$ -16.42NT$ -13.55NT$ -13.80
Weighted Average Shares Outstanding244.72M155.23M130.13M121.14M111.85M
Weighted Average Shares Outstanding (Diluted)244.72M155.23M130.13M121.14M111.85M

Currency in TWD

Tanvex Biopharma Earnings and Revenue History

-3B-1.5B01.5B-750000 %-500000 %-250000 %0 %EarningsProfit Margin201720182019202020212022202320242025RevenueEarningsProfit Margin